Abivax (ABVX) Reiterated at Market Outperform by Citizens on Positive ABTECT Data

July 1, 2026 4:39 AM

Citizens analyst Jason Butler reiterated a Market Outperform rating and $187.00 price target on Abivax (NASDAQ: ABVX).The analyst commented, "Insights ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found